Research article
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
-
* Corresponding author: Ivette F Emery emeryi@mccm.org
1 Department of Translational Research, Maine Center for Cancer Medicine, Scarborough, Maine, USA
2 Department of Internal Medicine, Maine Medical Center, Portland, Maine, USA
3 Department of Pathology, Maine Medical Center, Portland, Maine, USA
4 Histology Core, Maine Medical Center Research Institute, Scarborough, Maine, USA
BMC Cancer 2009, 9:333 doi:10.1186/1471-2407-9-333
Published: 18 September 2009Additional files
Additional file 1:
Immunohistochemistry scores. Thirty two patients had tissue available for immunohistochemical analysis. Detailed information about each tissue sample is listed on the second column. Patient information, such as performance status (ECOG) and the number of previous lines of chemotherapy at the time of TKI administration is also listed. IHCs were scored on a semiquantitative basis of percentage of positive tumour cells (0-100%), multiplied by staining intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong). The percentage of cells staining is shown for each antigen. Patients are listed according to increasing length of time to progression.
Format: DOC Size: 105KB Download file
This file can be viewed with: Microsoft Word Viewer
